Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 108B 392M 356M 329M 297M 561M 36.79B 580M 3.96B 1.57B 19.74B 1.47B 1.44B 62.53B P/E 2026 *
10.2x
P/E 2027 * 8.55x
Enterprise Value 108B 392M 356M 329M 297M 561M 36.79B 580M 3.96B 1.57B 19.74B 1.47B 1.44B 62.53B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.48x
Free-Float
16.89%
Yield 2026 *
5.31%
Yield 2027 * 5.74%
10-29 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
09-04 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
09-04 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
08-29 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026, Payable on September 11, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
06-01 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
1 day+0.96%
1 week+0.68%
Current month+6.32%
1 month+8.90%
3 months-1.48%
6 months-1.82%
Current year-12.88%
1 week 335
Extreme 335
347.39
1 month 305
Extreme 305
347.39
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.27
3 years 75.01
Extreme 75.01
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%+0.68%-13.75%+315.55% 387M
+0.13%+2.54%+41.71%+145.92% 1,286B
-0.17%+1.04%+42.81%+89.89% 688B
+0.56%+1.24%+26.90%+114.74% 521B
+1.14%+2.04%+42.51%+72.81% 386B
-0.77%-1.39%+57.97%+43.83% 364B
+1.27%+1.72%+28.34%+63.11% 302B
+0.37%-0.23%+3.25%+38.05% 287B
+0.49%+0.75%+37.16%+74.24% 252B
+0.82%+0.17%+36.68%+127.60% 208B
Average +0.39%+1.82%+30.36%+108.57% 429B
Weighted average by Cap. +0.24%+3.26%+37.52%+99.83%

Financials

2026 *2027 *
Net sales 68.81B 249M 226M 209M 189M 356M 23.38B 369M 2.51B 996M 12.55B 934M 915M 39.74B 73.23B 265M 241M 222M 201M 379M 24.88B 392M 2.67B 1.06B 13.35B 994M 973M 42.29B
Net income 10.49B 37.96M 34.48M 31.86M 28.78M 54.31M 3.56B 56.22M 383M 152M 1.91B 142M 139M 6.06B 12.43B 44.98M 40.86M 37.76M 34.1M 64.36M 4.22B 66.62M 454M 180M 2.27B 169M 165M 7.18B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pakistan Limited
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
16/11/26 PKR 339.59 +0.96% 118,978
13/11/26 PKR 336.36 -0.57% 97,426
12/11/26 PKR 338.29 -0.94% 107,149
11/11/26 PKR 341.49 +0.05% 267,402
10/11/26 PKR 341.33 +1.19% 136,549
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
339.59PKR
Average target price
510.00PKR
Spread / Average Target
+50.18%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GlaxoSmithKline Pakistan Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock